Effective upon the closing of the Merger on June 20, 2024, the size of the board of directors was fixed at six members and the board of directors of the Company was reconstituted as follows: (i) Phillip B. Donenberg (designated by AVROBIO), and (ii) Alise Reicin, M.D., Terrance McGuire, Timothy A. Springer, Ph.D., Praveen Tipirneni, M.D. and Stefan Vitorovic, M.S., M.B.A. (designated by Tectonic).
immediately prior to the Merger, Gail Farfel, Ph.D., Christopher Paige, Ph.D., Philip J. Vickers, Ph.D., Ian Clark, Annalisa Jenkins, M.B.B.S., F.R.C.P. and Bruce Booth, D.Phil. resigned from the AVROBIO’s board of directors and committees of the AVROBIO board of directors on which they respectively served, which resignations were not the result of any disagreements with the Company relating to its operations, policies or practices.
immediately prior to the Merger, Gail Farfel, Ph.D., Christopher Paige, Ph.D., Philip J. Vickers, Ph.D., Ian Clark, Annalisa Jenkins, M.B.B.S., F.R.C.P. and Bruce Booth, D.Phil. resigned from the AVROBIO’s board of directors and committees of the AVROBIO board of directors on which they respectively served, which resignations were not the result of any disagreements with the Company relating to its operations, policies or practices.
immediately prior to the Merger, Gail Farfel, Ph.D., Christopher Paige, Ph.D., Philip J. Vickers, Ph.D., Ian Clark, Annalisa Jenkins, M.B.B.S., F.R.C.P. and Bruce Booth, D.Phil. resigned from the AVROBIO’s board of directors and committees of the AVROBIO board of directors on which they respectively served, which resignations were not the result of any disagreements with the Company relating to its operations, policies or practices.
immediately prior to the Merger, Gail Farfel, Ph.D., Christopher Paige, Ph.D., Philip J. Vickers, Ph.D., Ian Clark, Annalisa Jenkins, M.B.B.S., F.R.C.P. and Bruce Booth, D.Phil. resigned from the AVROBIO’s board of directors and committees of the AVROBIO board of directors on which they respectively served, which resignations were not the result of any disagreements with the Company relating to its operations, policies or practices.
Effective upon the closing of the Merger on June 20, 2024, the size of the board of directors was fixed at six members and the board of directors of the Company was reconstituted as follows: (i) Phillip B. Donenberg (designated by AVROBIO), and (ii) Alise Reicin, M.D., Terrance McGuire, Timothy A. Springer, Ph.D., Praveen Tipirneni, M.D. and Stefan Vitorovic, M.S., M.B.A. (designated by Tectonic).
immediately prior to the Merger, Gail Farfel, Ph.D., Christopher Paige, Ph.D., Philip J. Vickers, Ph.D., Ian Clark, Annalisa Jenkins, M.B.B.S., F.R.C.P. and Bruce Booth, D.Phil. resigned from the AVROBIO’s board of directors and committees of the AVROBIO board of directors on which they respectively served, which resignations were not the result of any disagreements with the Company relating to its operations, policies or practices.
Effective upon the closing of the Merger on June 20, 2024, the size of the board of directors was fixed at six members and the board of directors of the Company was reconstituted as follows: (i) Phillip B. Donenberg (designated by AVROBIO), and (ii) Alise Reicin, M.D., Terrance McGuire, Timothy A. Springer, Ph.D., Praveen Tipirneni, M.D. and Stefan Vitorovic, M.S., M.B.A. (designated by Tectonic).
On June 18, 2024, Joanna Horobin, M.B., Ch.B. a member of the Board of Directors (the “Board”) of Kymera Therapeutics, Inc. (the “Company”) and the Audit Committee of the Board (the “Audit Committee”) and Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), notified the Company of her resignation from the Board and all committees thereof, effective immediately.
Appointed
Grace Bucchianeri
Director
STORE CAPITAL LLC
Effective
2024-06-15
Filed
June 20, 2024, 7:59 PM ET
On June 15, 2024, the board of directors (the “ Board ”) of STORE Capital LLC (the “ Company ”) authorized the appointment of Grace Bucchianeri to the Board, effective as of June 15, 2024.
On June 17, 2024, Anna French, D.Phil. notified the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) of her intent to resign from the Board effective as of June 18, 2024.
Effective immediately following Dr. French’s resignation, on June 18, 2024, the Board appointed Svetlana Lucas, Ph.D. as a Class III director of the Company.
Mr. Congjin Wang resigned as a member of the Board and the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee of the Board, including as chairperson of the Nominating and Corporate Governance Committee.
Mr. Xiaojin Tang resigned as a member of the Board and the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee of the Board, including as chairperson of the Compensation Committee.
Departed
Zhenai Shen
Director
Organic Agricultural Co Ltd
Effective
2024-06-18
Filed
June 20, 2024, 7:59 PM ET
On June 18, 2024 Zhenai Shen resigned from her position as a member of the Registrant’s Board of Directors.
Appointed
Steve J. Smith
Class II Director
Ault Disruptive Technologies Corp
Effective
2024-06-18
Filed
June 20, 2024, 7:59 PM ET
Effective June 18, 2024, Ault Disruptive Technologies Corporation, a Delaware corporation (the “ Company ”), appointed Steve J. Smith to its board of directors (the “ Board ”) as a Class II director.
Effective June 17, 2024, the Board of Directors (the “Board”) of MDB Capital Holdings, LLC (the “Company”) increased the size of the Board by one position to a total of eight directors and filled the vacancy created by the increase by appointing Mr. Daniel Torpey, age 60, as an independent director.
On June 14, 2024, the Board of Directors of Glucotrack, Inc. (the “Company”) appointed Andrew K. Balo to the Board of Directors as an independent board member.
On June 13, 2024, NRx Pharmaceuticals, Inc. (the “ Company ”) appointed Dr. Dennis McBride to serve as a member of the Board of Directors of the Company.
On June 16, 2024, Richard Wolford informed e.l.f. Beauty, Inc. (the “Company”) that he would not stand for re-election at the upcoming 2024 annual meeting of stockholders of the Company to be held on August 22, 2024 (the “2024 Annual Meeting”) and will resign from the Board of Directors of the Company (the “Board”) effective as of the 2024 Annual Meeting.
On June 20, 2024, the Board appointed Brian D. Hughes to the Board as a Class III director, effective July 1, 2024, with a term expiring at the Company’s 2026 annual meeting of stockholders.
On June 17, 2024, James D. White, Lead Independent Director of the Board of Directors (the “Board”) of Affirm Holdings, Inc. (the “Company”), resigned as a member of the Board, effective June 30, 2024.
On June 20, 2024, the Board appointed current Board member Christa S. Quarles to succeed Mr. White as Lead Independent Director effective July 1, 2024.
On June 17, 2024, Karen Drexler tendered her resignation from the Board and each of the Compensation Committee, Audit and Risk Committee and Nominations and Corporate Governance Committee thereof, in each case effective September 30, 2024.
On June 17, 2024, the board of directors (the “Board”) of Tivic Health Systems, Inc. (the “Company”) appointed Christina Valauri as a director of the Company, effective July 1, 2024
On June 17, 2024, Howard Hughes Holdings Inc., a Delaware corporation (the “Company”), appointed Dana Hamilton to serve on the Company’s board of directors (the “Board”)
On June 18, 2024, the Board of Directors (the “Board”) of Bristol-Myers Squibb Company (the “Company”) elected Mr. Michael R. McMullen to serve as a member of the Board, effective July 1, 2024.
the Board, upon the recommendation of its Nominating and Governance Committee, appointed Nathan K. Sleeper and John Stroup, each CD&R partners, as new members of the Board to serve until the 2025 annual meeting of stockholders of the Company.
the Board, upon the recommendation of its Nominating and Governance Committee, appointed Nathan K. Sleeper and John Stroup, each CD&R partners, as new members of the Board to serve until the 2025 annual meeting of stockholders of the Company.
Appointed
Takashi Fukui
director
Manitex International, Inc.
Effective
2024-06-18
Filed
June 18, 2024, 7:59 PM ET
the Company appointed Mr. Fukui to the Board, effective June 18, 2024.
Departed
Shinichi Iimura
director
Manitex International, Inc.
Effective
2024-06-17
Successor
Takashi Fukui
Filed
June 18, 2024, 7:59 PM ET
On June 17, 2024, Mr. Iimura notified the Company of his resignation from the Board, effective immediately, due to personal health reasons.
unanimously appointed John R. Tracy as a director and as a member of the Audit Committee of the Board, to be effective immediately following the filing of the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2024.
the Board appointed Ms. Donna Arduin Kauranen to serve as a director on the Board of GEO for a term expiring at the 2025 annual meeting of shareholders
On June 13, 2024, the board of directors (the “Board”) of Mativ Holdings, Inc. (the “Company”) appointed John K. Stipancich as an independent director to serve a term expiring at the Company’s 2027 annual meeting, effective immediately.
On June 12, 2024, Jeffrey Keenan, a member of the Board, resigned from the Board and the audit and nominating & governance committees of the Board, effective immediately.
On June 12, 2024, Lee Fraser resigned from the board of directors (the “Board”) and Audit Committee of the Board of Planet 13 Holdings Inc.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.